GlassScriptPhysician profile
Michael Mendoza
NPI 1255531331
$7,732.62
in general payments reported to CMS, 2019-2025
19 companies · $1,988 in 2025
The $1,988 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,406 · 2020: $437 · 2021: $799 · 2022: $1,492 · 2023: $399 · 2024: $1,212 · 2025: $1,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,598.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,692.18 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $1,233.46 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $967.27 | 2021-2025 | Tryptyr, Rocklatan, Precision7 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $737.04 | 2019-2021 | |
| Biotissue Holdings INC. | $640.61 | 2019-2024 | |
| Tarsus Pharmaceuticals, INC. | $485.33 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $364.56 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $353.96 | 2022-2025 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $280.60 | 2020-2024 | Misight Contact Lens, Myday Contact Lens, Paragon Crt |
| Dompe US, INC. | $269.54 | 2022-2025 | Oxervate |
| Abbvie INC. | $204.62 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $152.16 | 2019-2021 | |
| Glaukos Corporation | $127.67 | 2022 | |
| Optovue, INC. | $71.40 | 2019 | |
| Rxsight INC | $64.33 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Contact Lens |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $39.47 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $19.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.81 | 2019 | |
| Shire North American Group INC | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mendoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.